Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-11 4:22 pm Purchase |
2024-10-04 | 13G | OnKure Therapeutics, Inc. OKUR |
Cormorant Asset Management LP | 1,895,717 14.980% |
1,895,717 (New Position) |
Filing History |
| 2024-06-20 4:01 pm Purchase |
2024-06-10 | 13G | Rapport Therapeutics, Inc. Common Stock RAPP |
Cormorant Asset Management LP | 2,940,283 8.040% |
2,940,283 (New Position) |
Filing History |
| 2024-05-13 4:00 pm Purchase |
2024-05-02 | 13G | CytomX Therapeutics, Inc. CTMX |
Cormorant Asset Management LP | 5,750,000 7.380% |
5,750,000 (New Position) |
Filing History |
| 2024-04-29 4:02 pm Purchase |
2024-04-19 | 13G | TScan Therapeutics, Inc. TCRX |
Cormorant Asset Management LP | 2,500,000 5.150% |
2,500,000 (New Position) |
Filing History |
| 2024-04-15 6:10 pm Sale |
2024-04-03 | 13G | Immuneering Corporation IMRX |
Cormorant Asset Management LP | 1,700,000 5.810% |
-2,504,364 (-59.57%) |
Filing History |
| 2024-03-21 4:02 pm Purchase |
2024-03-11 | 13G | Ventyx Biosciences, Inc. VTYX |
Cormorant Asset Management LP | 3,670,000 5.210% |
3,670,000 (New Position) |
Filing History |
| 2024-03-18 4:11 pm Purchase |
2024-03-08 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP |
Cormorant Asset Management LP | 2,025,000 19.300% |
2,025,000 (New Position) |
Filing History |
| 2024-02-14 3:08 pm Purchase |
2023-12-31 | 13G | Neurogene Inc. NGNE |
Cormorant Asset Management LP | 746,180 5.820% |
746,180 (New Position) |
Filing History |
| 2024-02-14 3:08 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 1,211,696 4.380% |
-745,436 (-38.09%) |
Filing History |
| 2024-02-14 3:08 pm Purchase |
2023-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA |
Cormorant Asset Management LP | 2,456,800 4.490% |
374,800 (+18.00%) |
Filing History |
| 2024-02-14 3:07 pm Sale |
2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN |
Cormorant Asset Management LP | 2,550,000 4.390% |
-300,000 (-10.53%) |
Filing History |
| 2024-02-14 3:07 pm Purchase |
2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Cormorant Asset Management LP | 3,250,000 5.960% |
450,000 (+16.07%) |
Filing History |
| 2024-02-14 3:05 pm Purchase |
2023-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX |
Cormorant Asset Management LP | 633,345 7.390% |
633,345 (New Position) |
Filing History |
| 2024-02-14 3:04 pm Purchase |
2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 2,221,422 6.710% |
485,000 (+27.93%) |
Filing History |
| 2024-02-14 3:04 pm Purchase |
2023-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH |
Cormorant Asset Management LP | 2,141,506 9.990% |
339,559 (+18.84%) |
Filing History |
| 2024-02-14 3:03 pm Sale |
2023-12-31 | 13G | Korro Bio, Inc. KRRO |
Cormorant Asset Management LP | 529,170 6.610% |
-150,000 (-22.09%) |
Filing History |
| 2024-02-14 3:03 pm Purchase |
2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Cormorant Asset Management LP | 11,231,000 17.780% |
11,231,000 (New Position) |
Filing History |
| 2024-02-14 3:02 pm Sale |
2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
Cormorant Asset Management LP | 0 0.000% |
-2,893,717 (Position Closed) |
Filing History |
| 2024-02-14 3:02 pm Sale |
2023-12-31 | 13G | Elevation Oncology, Inc. ELEV |
Cormorant Asset Management LP | 0 0.000% |
-1,952,032 (Position Closed) |
Filing History |
| 2024-02-14 3:01 pm Unchanged |
2023-12-31 | 13G | Eledon Pharmaceuticals, Inc. ELDN |
Cormorant Asset Management LP | 0 0.000% |
0 (Unchanged) |
Filing History |